Literature DB >> 20676905

LC/MS evaluation of metabolism and membrane transport of bombesin peptides.

Dongyu Gu1, Ying Ma, Gang Niu, Yongjun Yan, Lixin Lang, Haji Akber Aisa, Haji Akber Aisaand, Haokao Gao, Dale O Kiesewetter, Xiaoyuan Chen.   

Abstract

Two bombsin peptides, GRPR agonist [Aca-QWAVGHLM-NH(2)] and antagonist [fQWAVGHL-NHEthyl] were evaluated. We employed the highly sensitive Waters Q-Tof Premier MS coupled with a UPLC system to identify the metabolites produced by rat hepatocytes or PC-3 human prostate cancer cells; and we utilized the AB/MDS 4000 Q-Trap LC/MS/MS system with highly sensitive quantitative and qualitative performance, to quantitatively analyze the internalization of GRPR agonist and antagonist in PC-3 cells. The major metabolites of both GRPR agonist and antagonist were the result of peptide bond hydrolysis between W and A which was demonstrated by observation of the N-terminal fragment m/z 446 (Aca-QW-OH) for agonist and m/z 480 (fQW-OH) for antagonist. Both peptides were also hydrolyzed between A and V which formed peaks m/z 517 [Aca-QWA-OH] and m/z 555 (VGHLM-NH2) for the agonist and m/z 551 [fQWA-OH] and m/z 452 (VGHL-NHEthyl) for the antagonist. The peptide agonist also formed a unique metabolite that resulted from hydrolysis of the C-terminal amide. The antagonist showed significantly slower metabolism as compared to the agonist in both rat hepatocytes and PC-3 cells. The antagonist also showed significantly lower PC-3 cell internalization rate than that of the agonist. In conclusion, the metabolism profiles of both GRPR agonist and antagonist peptides were identified by LC/MS. The antagonist peptide was more stable than the agonist peptide in rat hepatocyte incubation. One major factor could be the hydrolysis-resistant C-terminal L-NHEthyl group compared with the unsubstituted amide of the agonist. Another factor could be different amino acid sequences of the agonist and antagonist that may also influence the enzymatic hydrolysis. The antagonist ligand is potentially more useful for receptor-targeted imaging due primarily to its higher metabolic stability.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20676905      PMCID: PMC3020998          DOI: 10.1007/s00726-010-0696-y

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  20 in total

1.  Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma.

Authors:  Yi-Shan Yang; Xianzhong Zhang; Zhengming Xiong; Xiaoyuan Chen
Journal:  Nucl Med Biol       Date:  2006-03-09       Impact factor: 2.408

2.  Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast.

Authors:  M Gugger; J C Reubi
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung.

Authors:  M A Shipp; G E Tarr; C Y Chen; S N Switzer; L B Hersh; H Stein; M E Sunday; E L Reinherz
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

Review 4.  Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes.

Authors:  Charles J Smith; Wynn A Volkert; Timothy J Hoffman
Journal:  Nucl Med Biol       Date:  2005-10       Impact factor: 2.408

Review 5.  Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy.

Authors:  D B Cornelio; R Roesler; G Schwartsmann
Journal:  Ann Oncol       Date:  2007-03-09       Impact factor: 32.976

6.  Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation.

Authors:  R Markwalder; J C Reubi
Journal:  Cancer Res       Date:  1999-03-01       Impact factor: 12.701

7.  microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.

Authors:  Xiaoyuan Chen; Ryan Park; Yingping Hou; Michel Tohme; Antranik H Shahinian; James R Bading; Peter S Conti
Journal:  J Nucl Med       Date:  2004-08       Impact factor: 10.057

8.  [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging.

Authors:  Berthold Nock; Anastasia Nikolopoulou; Efstratios Chiotellis; George Loudos; Dimitrios Maintas; Jean Claude Reubi; Theodosia Maina
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-11-29       Impact factor: 9.236

9.  Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors.

Authors:  Hanwen Zhang; Jianhua Chen; Christian Waldherr; Karin Hinni; Beatrice Waser; Jean Claude Reubi; Helmut R Maecke
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

10.  18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer.

Authors:  Xianzhong Zhang; Weibo Cai; Feng Cao; Eduard Schreibmann; Yun Wu; Joseph C Wu; Lei Xing; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2006-03       Impact factor: 10.057

View more
  3 in total

1.  Evaluation of fluorine-labeled gastrin-releasing peptide receptor (GRPR) agonists and antagonists by LC/MS.

Authors:  Ying Ma; Min Yang; Haokao Gao; Gang Niu; Yongjun Yan; Lixin Lang; Dale O Kiesewetter; Xiaoyuan Chen
Journal:  Amino Acids       Date:  2012-02-22       Impact factor: 3.520

2.  Rational design of matrix metalloproteinase-13 activatable probes for enhanced specificity.

Authors:  Lei Zhu; Ying Ma; Dale O Kiesewetter; Ye Wang; Lixin Lang; Seulki Lee; Gang Niu; Xiaoyuan Chen
Journal:  ACS Chem Biol       Date:  2013-12-03       Impact factor: 5.100

3.  Combined image guided monitoring the pharmacokinetics of rapamycin loaded human serum albumin nanoparticles with a split luciferase reporter.

Authors:  Fu Wang; Kai Yang; Zhe Wang; Ying Ma; J Silvio Gutkind; Naoki Hida; Gang Niu; Jie Tian
Journal:  Nanoscale       Date:  2016-02-21       Impact factor: 7.790

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.